A protein-tyrosine kinase receptor that is closely related in structure to the INSULIN RECEPTOR. Although commonly referred to as the IGF-I receptor, it binds both IGF-I and IGF-II with high affinity. It is comprised of a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The beta subunit contains an intrinsic tyrosine kinase domain.
A receptor that is specific for IGF-II and mannose-6-phosphate. The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF TYPE 1) and does not have a tyrosine kinase domain.
A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.
A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults.
Insulin-like polypeptides made by the liver and some fibroblasts and released into the blood when stimulated by SOMATOTROPIN. They cause sulfate incorporation into collagen, RNA, and DNA synthesis, which are prerequisites to cell division and growth of the organism.
The variable phenotypic expression of a GENE depending on whether it is of paternal or maternal origin, which is a function of the DNA METHYLATION pattern. Imprinted regions are observed to be more methylated and less transcriptionally active. (Segen, Dictionary of Modern Medicine, 1992)
A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (Int J Gynaecol Obstet 1992;39(1):3-9)
One of the six homologous soluble proteins that bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions at the cellular level.

In-vitro fertilization and culture of mouse embryos in vitro significantly retards the onset of insulin-like growth factor-II expression from the zygotic genome. (1/794)

In this study, the effect of in-vitro fertilization (IVF) and culture of mouse embryos in vitro on the normal expression of insulin-like growth factor-II (IFG-II) ligand and receptor was examined. The expression of IGF-II increased in a linear fashion at least up to the 8-cell stage of development. IGF-II expression in embryos collected fresh from the reproductive tract was significantly (P < 0.001) greater than in embryos fertilized in the reproductive tract and cultured in vitro (in-situ fertilized: ISF), and its expression was further reduced (P < 0.001) in IVF embryos at all development stages tested. The expression of IGF-II was significantly (P < 0.001) lower when embryos were cultured individually in 100 microl drops compared with culture in groups of 10 in 10 microl drops of medium. The addition of platelet activating factor to culture medium partially overcame this density-dependent decline of expression. Culture of ISF and IVF zygotes also caused the onset of new IGF-II mRNA transcription from the zygotic genome to be significantly (P < 0.001) retarded, until at least the 8-cell stage of development. This effect was greater (P < 0.05) for IVF than for ISF embryos. Neither IVF nor culture had any obvious effect on IFG-II/mannose-6-phosphate receptor (IGF-IIr) mRNA expression.  (+info)

High-affinity binding of the AP-1 adaptor complex to trans-golgi network membranes devoid of mannose 6-phosphate receptors. (2/794)

The GTP-binding protein ADP-ribosylation factor (ARF) initiates clathrin-coat assembly at the trans-Goli network (TGN) by generating high-affinity membrane-binding sites for the AP-1 adaptor complex. Both transmembrane proteins, which are sorted into the assembling coated bud, and novel docking proteins have been suggested to be partners with GTP-bound ARF in generating the AP-1-docking sites. The best characterized, and probably the major transmembrane molecules sorted into the clathrin-coated vesicles that form on the TGN, are the mannose 6-phosphate receptors (MPRs). Here, we have examined the role of the MPRs in the AP-1 recruitment process by comparing fibroblasts derived from embryos of either normal or MPR-negative animals. Despite major alterations to the lysosome compartment in the MPR-deficient cells, the steady-state distribution of AP-1 at the TGN is comparable to that of normal cells. Golgi-enriched membranes prepared from the receptor-negative cells also display an apparently normal capacity to recruit AP-1 in vitro in the presence of ARF and either GTP or GTPgammaS. The AP-1 adaptor is recruited specifically onto the TGN and not onto the numerous abnormal membrane elements that accumulate within the MPR-negative fibroblasts. AP-1 bound to TGN membranes from either normal or MPR-negative fibroblasts is fully resistant to chemical extraction with 1 M Tris-HCl, pH 7, indicating that the adaptor binds to both membrane types with high affinity. The only difference we do note between the Golgi prepared from the MPR-deficient cells and the normal cells is that AP-1 recruited onto the receptor-lacking membranes in the presence of ARF1.GTP is consistently more resistant to extraction with Tris. Because sensitivity to Tris extraction correlates well with nucleotide hydrolysis, this finding might suggest a possible link between MPR sorting and ARF GAP regulation. We conclude that the MPRs are not essential determinants in the initial steps of AP-1 binding to the TGN but, instead, they may play a regulatory role in clathrin-coated vesicle formation by affecting ARF.GTP hydrolysis.  (+info)

The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. (3/794)

Niemann-Pick C disease (NP-C) is a neurovisceral lysosomal storage disorder. A variety of studies have highlighted defective sterol trafficking from lysosomes in NP-C cells. However, the heterogeneous nature of additional accumulating metabolites suggests that the cellular lesion may involve a more generalized block in retrograde lysosomal trafficking. Immunocytochemical studies in fibroblasts reveal that the NPC1 gene product resides in a novel set of lysosome-associated membrane protein-2 (LAMP2)(+)/mannose 6-phosphate receptor(-) vesicles that can be distinguished from cholesterol-enriched LAMP2(+) lysosomes. Drugs that block sterol transport out of lysosomes also redistribute NPC1 to cholesterol-laden lysosomes. Sterol relocation from lysosomes in cultured human fibroblasts can be blocked at 21 degrees C, consistent with vesicle-mediated transfer. These findings suggest that NPC1(+) vesicles may transiently interact with lysosomes to facilitate sterol relocation. Independent of defective sterol trafficking, NP-C fibroblasts are also deficient in vesicle-mediated clearance of endocytosed [14C]sucrose. Compartmental modeling of the observed [14C]sucrose clearance data targets the trafficking defect caused by mutations in NPC1 to an endocytic compartment proximal to lysosomes. Low density lipoprotein uptake by normal cells retards retrograde transport of [14C]sucrose through this same kinetic compartment, further suggesting that it may contain the sterol-sensing NPC1 protein. We conclude that a distinctive organelle containing NPC1 mediates retrograde lysosomal transport of endocytosed cargo that is not restricted to sterol.  (+info)

Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. (4/794)

Viable mice nullizygous in genes encoding the 300 kDa and the 46 kDa mannose 6-phosphate receptors (MPR 300 and MPR 46) and the insulin like growth factor II (IGF II) were generated to study the trafficking of lysosomal enzymes in the absence of MPRs. The mice have an I-cell disease-like phenotype, with increase of lysosomal enzymes in serum and normal activities in tissues. Surprisingly, the ability of MPR-deficient cells to transport newly synthesized lysosomal enzymes to lysosomes and the underlying mechanisms were found to depend on the cell type. MPR-deficient thymocytes target newly synthesized cathepsin D to lysosomes via an intracellular route. In contrast, hepatocytes and fibroblasts secrete newly synthesized cathepsin D. In fibroblasts recapture of secreted lysosomal enzymes, including that of cathepsin D, is limited and results in lysosomal storage, both in vivo and in vitro, whereas recapture by hepatocytes is remarkably effective in vivo and can result in lysosomal enzyme levels even above normal.  (+info)

Microsatellite instability is uncommon in breast cancer. (5/794)

In some tumors, defects in mismatch repair enzymes lead to errors in the replication of simple nucleotide repeat segments. This condition is commonly known as microsatellite instability (MSI) because of the frequent mutations of microsatellite sequences. Although the MSI phenotype is well recognized in some colon, gastric, pancreatic, and endometrial cancers, reports of MSI in breast cancer are inconsistent. We report here our experience with >10,000 amplifications of simple nucleotide repeats in noncoding genomic regions using DNA from 267 cases of breast cancer, including cases that represent all major histological types of breast cancer. We rarely (10 reactions) found unexpected bands in amplifications of tumor DNA that were not present in amplifications of normal DNA. Moreover, repeats of these reactions did not confirm microsatellite instability in a single case. We also evaluated the simple nucleotide repeats in the transforming growth factor type II receptor, insulin-like growth factor type II receptor, BAX, and E2F-4 genes, which are frequently mutated in tumors with microsatellite instability. No mutations of these genes were found in any of the 30 breast cancer cell lines and 61 primary breast cancer samples examined. These results indicate that mismatch repair errors characteristic of the MSI phenotype are uncommon in human breast cancer.  (+info)

The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. (6/794)

We have characterized the temporal expression of the insulin-like growth factor (IGF) axis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model as prostate cancer progression in this model closely mimics that observed in the human disease, and the model provides samples representing the earliest stages of prostate cancer that are clinically the most difficult to obtain. We report that prostate-specific IGF-I mRNA expression increased during prostate cancer progression in TRAMP mice and was elevated in the accompanying metastatic lesions, whereas prostatic IGF-I mRNA remained at nontransgenic levels in androgen-independent disease. Expression of IGF-II mRNA, however, was reduced in primary prostate cancer, metastatic lesions, and androgen-independent disease. Expression of type-1 IGF receptor (IGF1R) mRNA, encoding the cognate receptor for both IGF-I and IGF-II, as well as type-2 IGF receptor (IGF2R) mRNA was not found to be altered during primary prostate cancer progression in intact TRAMP mice but was dramatically reduced in metastatic lesions and in androgen-independent disease. Similar to reports from clinical disease, serum IGF-I levels were observed to increase precociously in TRAMP mice early in disease progression but remained at nontransgenic levels after castration. Elevated serum levels of IGF-binding protein 2 were observed to correlate with advanced prostate cancer in the TRAMP model. Together these observations implicate IGF-I as an important factor during the initiation and progression of primary prostate cancer and provide evidence that there is a strong selection against expression of IGF1R and IGF2R in metastatic and androgen-independent disease.  (+info)

Phosphorylation of arylsulphatase A occurs through multiple interactions with the UDP-N-acetylglucosamine-1-phosphotransferase proximal and distal to its retrieval site by the KDEL receptor. (7/794)

Phosphorylation of oligosaccharides of the lysosomal enzyme arylsulphatase A (ASA), which accumulate in the secretions of cells that mis-sort most of the newly synthesized lysosomal enzymes due to a deficiency of mannose 6-phosphate receptors, was found to be site specific. ASA residing within the secretory route of these cells contains about one third of the incorporated [2-3H]mannose in phosphorylated oligosaccharides. Oligosaccharides carrying two phosphate groups are almost 2-fold less frequent than those with one phosphate group and only a few of the phosphate groups are uncovered. Addition of a KDEL (Lys-Asp-Glu-Leu) retention signal prolongs the residence time of ASA within the secretory route 6-fold, but does not result in more efficient phosphorylation. In contrast, more than 90% of the [2-3H]mannose incorporated into secreted ASA (with or without a KDEL retention signal) is present in phosphorylated oligosaccharides. Those with two phosphate groups are almost twice as frequent as those with one phosphate group and most of the phosphate groups are uncovered. Thus, ASA receives N-acetylglucosamine 1-phosphate groups in a sequential manner at two or more sites located within the secretory route proximal and distal to the site where ASA is retrieved by the KDEL receptor, i.e. proximal to the trans-Golgi. At each of these sites up to two N-acetylglucosamine 1-phosphate groups can be added to a single oligosaccharide. Of several drugs known to inhibit transit of ASA through the secretory route only the ionophore monensin had a major inhibitory effect on phosphorylation, uncovering and sialylation.  (+info)

Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. (8/794)

The majority of tumors from hereditary nonpolyposis colorectal cancer families and a subset of unselected gastrointestinal and endometrial tumors exhibit a microsatellite mutator phenotype (MMP) that leads to the accumulation of hundreds of thousands of clonal mutations in simple repeat sequences. The mutated genes with positive or negative roles in cell growth or survival in aneuploid gastrointestinal cancer (e.g., APC, K-ras, and p53) are less frequently mutated in near-diploid MMP gastrointestinal tumors. These tumors accumulate mutations in other genes, such as DNA mismatch repair hMSH3 and hMSH6, transforming growth factor-beta type II receptor, and BAX. All these genes carry, within their coding sequences, mononucleotide repeats that are preferred targets for the MMP. Endometrial carcinoma is the most common type of extracolonic neoplasia in the hereditary nonpolyposis colorectal cancer syndrome, but the spectrum of its target cancer genes is not well characterized. Here, we report that endometrial cancer of the MMP also accumulates mutations in genes that are typically mutated in gastrointestinal cancer of the mutator pathway, including BAX (55%), hMSH3 (28%), and hMSH6 (17%). We also report the detection of frameshift mutations in caspase-5, a member of the caspase family of proteases that has an (A)10 repeat within its coding region, in MMP tumors of the endometrium, colon, and stomach (28, 62, and 44%, respectively). We therefore suggest caspase-5 as a new target gene in the microsatellite mutator pathway for cancer.  (+info)

IGF-1R (Insulin-like Growth Factor 1 Receptor) is a transmembrane receptor tyrosine kinase that plays a crucial role in intracellular signaling pathways related to cell growth, differentiation, and survival. IGF-1R is primarily activated by its ligands, IGF-1 (Insulin-like Growth Factor 1) and IGF-2 (Insulin-like Growth Factor 2). Upon binding of the ligand, IGF-1R undergoes autophosphorylation and initiates a cascade of intracellular signaling events, primarily through the PI3K/AKT and RAS/MAPK pathways. These signaling cascades ultimately regulate various cellular processes such as glucose metabolism, protein synthesis, DNA replication, and cell cycle progression. Dysregulation of IGF-1R has been implicated in several diseases, including cancer, diabetes, and growth disorders.

IGF-2 (Insulin-like Growth Factor 2) receptor is a type of transmembrane protein that plays a role in cell growth, differentiation, and survival. Unlike other receptors in the insulin and IGF family, IGF-2 receptor does not mediate the activation of intracellular signaling pathways upon binding to its ligand (IGF-2). Instead, it acts as a clearance receptor that facilitates the removal of IGF-2 from circulation by transporting it to lysosomes for degradation.

The IGF-2 receptor is also known as cation-independent mannose-6-phosphate receptor (CI-M6PR) because it can also bind and transport mannose-6-phosphate-containing enzymes to lysosomes for degradation.

Mutations in the IGF-2 receptor gene have been associated with certain types of cancer, as well as developmental disorders such as Beckwith-Wiedemann syndrome.

Insulin-like growth factor I (IGF-I) is a hormone that plays a crucial role in growth and development. It is a small protein with structural and functional similarity to insulin, hence the name "insulin-like." IGF-I is primarily produced in the liver under the regulation of growth hormone (GH).

IGF-I binds to its specific receptor, the IGF-1 receptor, which is widely expressed throughout the body. This binding activates a signaling cascade that promotes cell proliferation, differentiation, and survival. In addition, IGF-I has anabolic effects on various tissues, including muscle, bone, and cartilage, contributing to their growth and maintenance.

IGF-I is essential for normal growth during childhood and adolescence, and it continues to play a role in maintaining tissue homeostasis throughout adulthood. Abnormal levels of IGF-I have been associated with various medical conditions, such as growth disorders, diabetes, and certain types of cancer.

Insulin-like Growth Factor II (IGF-II) is a growth factor that is structurally and functionally similar to insulin. It is a single-chain polypeptide hormone, primarily produced by the liver under the regulation of growth hormone. IGF-II plays an essential role in fetal growth and development, and continues to have important functions in postnatal life, including promoting cell growth, proliferation, and differentiation in various tissues.

IGF-II binds to and activates the IGF-I receptor and the insulin receptor, leading to intracellular signaling cascades that regulate metabolic and mitogenic responses. Dysregulation of IGF-II expression and signaling has been implicated in several pathological conditions, such as cancer, growth disorders, and diabetes.

It is important to note that IGF-II should not be confused with Insulin-like Growth Factor I (IGF-I), which is another hormone with structural and functional similarities to insulin but has distinct roles in growth and development.

Somatomedins are a type of insulin-like growth factors (IGFs), specifically IGF-1 and IGF-2. They are peptide hormones that play an essential role in the regulation of growth, development, and metabolism in the human body. Somatomedins are primarily produced by the liver in response to stimulation by growth hormone (GH) and act as mediators of GH's effects on cell growth, differentiation, and survival. They also have important functions in glucose homeostasis, energy metabolism, and tissue repair. Somatomedins exert their actions by binding to specific receptors on the surface of target cells, leading to intracellular signaling cascades that regulate various cellular processes.

Genomic imprinting is a epigenetic process that leads to the differential expression of genes depending on their parental origin. It involves the methylation of certain CpG sites in the DNA, which results in the silencing of one of the two copies of a gene, either the maternal or paternal allele. This means that only one copy of the gene is active and expressed, while the other is silent.

This phenomenon is critical for normal development and growth, and it plays a role in the regulation of genes involved in growth and behavior. Genomic imprinting is also associated with certain genetic disorders, such as Prader-Willi and Angelman syndromes, which occur when there are errors in the imprinting process that lead to the absence or abnormal expression of certain genes.

It's important to note that genomic imprinting is a complex and highly regulated process that is not yet fully understood. Research in this area continues to provide new insights into the mechanisms underlying gene regulation and their impact on human health and disease.

Insulin-like growth factor binding proteins (IGFBPs) are a family of proteins that bind to and regulate the biological activity of insulin-like growth factors (IGFs), specifically IGF-1 and IGF-2. There are six distinct IGFBPs (IGFBP-1 to IGFBP-6) in humans, each with unique structural features, expression patterns, and functions.

The primary function of IGFBPs is to modulate the interaction between IGFs and their cell surface receptors, thereby controlling IGF-mediated intracellular signaling pathways involved in cell growth, differentiation, and survival. IGFBPs can either enhance or inhibit IGF actions depending on the specific context, such as cell type, subcellular localization, and presence of other binding partners.

In addition to their role in IGF regulation, some IGFBPs have IGF-independent functions, including direct interaction with cell surface receptors, modulation of extracellular matrix composition, and participation in cell migration and apoptosis. Dysregulation of IGFBP expression and function has been implicated in various pathological conditions, such as cancer, diabetes, and cardiovascular diseases.

Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) is a protein that binds to and regulates the bioavailability and activity of Insulin-like Growth Factors (IGFs), specifically IGF-1 and IGF-2. It plays a crucial role in the growth, development, and homeostasis of various tissues and organs by modulating IGF signaling. IGFBP-3 is the most abundant IGF binding protein in circulation and has a longer half-life than IGFs, allowing it to act as a reservoir and transport protein for IGFs. Additionally, IGFBP-3 has been found to have IGF-independent functions, including roles in cell growth, differentiation, apoptosis, and tumor suppression.

These known SNPs of these IGF-1 axis genes appear to play minor roles in the risk for development of CPP. ... Receptor, IGF Type 1 / blood Actions. * Search in PubMed * Search in MeSH ... IGF-1 v.s IGF-1(6093)(GG), IGF-1R(GG), IGFBP-3(AA); b. IGF-1 v.s IGF-2(3580)(GG), IGF-2R(GG), IGFBP-3(AA); c. Z score of weight ... IGF-1 v.s IGF-1(6093)(GG), IGFBP-3(AA); e. IGF-1 v.s IGF-2(3580)(GG), IGFBP-3(AA); f. IGF-1 v.s IGF-1(3123(AA), IGFBP-3(AA)) ...
Insulin facilitates this in vitro mediated by the IGF-1 receptor. Clinical trials showed that the number of circulating EPCs is ... 73 patients with type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria were enrolled in this ... show that insulin stimulates the in vitro outgrowth of EPC and tube formation of adult endothelial cells in an IGF-1 receptor ... Methods 55 patients with type 2 diabetes (61.6±5.9 years) on oral diabetes medication were randomized in a 2:2:1 ratio in 3 ...
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal ... Background: Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), ... Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative ... a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory ...
Receptor, IGF Type 1 / metabolism* * Receptors, G-Protein-Coupled / metabolism * Trans-Activators / genetics ... or the ligand-dependent activation of LPA receptors or muscarinic receptors, which are two classes of G protein-coupled ... E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases EMBO J. 2004 Apr 21;23(8 ... the ligand-dependent activation of divergent classes of receptor tyrosine kinases (RTKs), by inhibiting their ligand-dependent ...
... suppresses components of the IGF regulatory system in different cell types, specifically blocking IGF-1 and IGF-2, as well as ... The activity of bisphenol A depends on both the estrogen receptor subtype and the cell type. Endocr J 49(4):465-471. 12402979. ... Peroxisome Proliferator-Activated Receptor-γ Mediates Bisphenol A Inhibition of FSH-Stimulated IGF-1, Aromatase, and Estradiol ... Interestingly, we also observed that BPA treatment dramatically reduced expression of IGF-1, thereby reducing IGF/FSH synergy, ...
Plasma insulin-like growth factors (IGFs), IGF-Binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in ... Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20. 342(16):1171-7. [ ... Dopamine agonists bind to pituitary dopamine type 2 (D2) receptors and suppress GH secretion, although the precise mechanism of ... IGF-I levels are normalized in as many as 90% of patients treated daily with this drug for 3 months. ...
Receptor, IGF Type 2/genetics; Transforming Growth Factor beta/genetics ... and the mannose 6-phosphate/insulin-like growth factor II receptor were significantly increased by EE treatment. Ten cDNA ...
In C. elegans, the insulin/IGF-1/FOXO pathway is initiated by changes in IGF-1 levels which cause IGF-1 receptors to start a ... Wild type C. elegans fed a diet that included 2% glucose showed reduced Daf-16 activity and lifespan was shortened by 20% ... identical to the IGF-1 receptor, which regulates growth; and 33% identical to the human insulin receptor-related receptor. ... The protein predicted from DAF-2s sequence is 35% identical to the human insulin receptor, which regulates metabolism; 34% ...
... a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 1989;3:1701 ... Breast size and risk of type 2 diabetes mellitus. Joel G. Ray, Anshu P. Mohllajee, Rob M. van Dam and Karin B. Michels ... Assessment of type 2 diabetes mellitus. We assessed the incident onset of type 2 diabetes between 1993 (when the Nurses Health ... Moreover, the risk of type 2 diabetes in relation to larger bra cup size was only modest. On the other hand, we found BMI at ...
TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.. Krieger CC; ... TSH/IGF-1 Receptor Cross Talk in Graves Ophthalmopathy Pathogenesis.. Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; ... Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves disease immunoglobins. ... 7. A Gq Biased Small Molecule Active at the TSH Receptor.. Latif R; Morshed SA; Ma R; Tokat B; Mezei M; Davies TF. Front ...
2012). In the context of RT, androgen receptor content correlates with an increase in lean mass and m. vastus lateralis type 1 ... 2014). Since IGF-1 data were not reported in the studies included in this review, we solely focused on testosterone changes ... de Alcantara Borba D, da Silva AE, Rosa JPP, Facundo LA, Costa CMA, Silva AC, Narciso FV, Silva A, de Mello MT (2020) Can IGF-1 ... 2012; Hamdi and Mutungi 2010), mTOR and Akt signaling, as well as androgen receptor activation (Basualto-Alarcón et al. 2013), ...
... the Type 1 IGF-1 receptor, which is homologous to the insulin receptor, is activated by IGF-1, leading to intracellular ... IGF-1 receptors are present on most types of cells and tissues. IGF-1 has mitogenic activities that lead to an increased number ... Distribution - In blood, IGF-1 is bound to six IGF binding proteins, with , 80% bound as a complex with IGFBP-3 and an acid- ... IGF-1 (ng/mL): 21.6 ± 20.6; IGF-1 SDS: -4.3 ± 1.6; and bone age (years): 4.2 ± 2.8. Sixty-one subjects had at least one year of ...
Receptor, IGF Type 1 beta Subunit*Receptor, IGF Type 1 beta Subunit ... Receptor, IGF Type 1 alpha Subunit*Receptor, IGF Type 1 alpha Subunit ... IGF Type 1" by people in this website by year, and whether "Receptor, IGF Type 1" was a major or minor topic of these ... Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]. *Receptor, IGF Type 1 [D08.811.913.696.620.682.725.400.185 ...
Serum IGF-I and total IGFBP-3 levels were significantly higher in individuals with impaired glucose tolerance and type 2 ... The IGF-I-IGFBP-3 axis, especially IGFBP-3, may be involved in the pathogenesis and metabolic control of glucose intolerance, ... Serum IGF-I and total IGFBP-3 levels, fasting plasma glucose levels, lipid profiles, insulin levels, C-peptide levels, ... In the DM group, serum IGF-I and total IGFBP-3 levels were positively correlated with fasting plasma glucose and HbA1c levels. ...
... receptor agonist for type 2 diabetes and severe obesity; and KT-A832, a gene therapy administered by intrapancreatic injection ... that delivers the gene to produce modified insulin growth factor 1 (IGF-1) for type 1 diabetes. ... The companys pipeline includes multiple AAV-based gene therapies for type 1 and type 2 diabetes, severe obesity, and other ... a gene therapy for delivering genes intramuscularly to produce insulin and glucokinase for types 1 and 2 diabetes; KT-A522, a ...
... chemokine receptor type 2; Drd4, dopamine receptor D4; FGF2, fibroblast growth element 2; HGF, hepatocyte growth element; IGF-1 ... insulin-like growth element 1; IGF-1R, insulin-like growth.. Search for:. ... F4/80 positive cells increased three to five-fold in wild type, Rag1KO, and IFNKO L635-treated mice compared to untreated mice ... Susceptible adult animal models of ZIKV pathogenesis that recapitulate neurotropic disease exploit IFN receptor gene knockouts/ ...
Receptor, IGF Type 2. *Muscle, Skeletal. *Mice, Knockout. *Mice. *Glycogen Storage Disease Type II ... The greatest impact upon gene therapy was observed in GAA-KO mice lacking the mannose-6-phosphate receptor in muscle. The ... Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in ... "Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in ...
The GHR gene provides instructions for making a protein called the growth hormone receptor. Learn about this gene and related ... Defects of the growth hormone receptor and their clinical implications. Growth Horm IGF Res. 1999 Apr;9 Suppl A:57-61. doi: ... Resistance to the effects of insulin is a major risk factor for type 2 diabetes. People with Laron syndrome have the opposite ... The GHR gene provides instructions for making a protein called the growth hormone receptor. This receptor is embedded in the ...
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II. RECEPTOR, IGF TYPE 2. RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR. RECEPTOR, ... RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I. RECEPTOR, IGF TYPE 1. ... RECEPTOR, EPIDERMAL GROWTH FACTOR. RECEPTORS, INSULIN. RECEPTOR ...
Mannose-6-Phosphate Receptor Receptor, IGF-II Receptor, Insulin-Like Growth Factor II Receptor, Insulin-Like Growth Factor Type ... The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF ... The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF ... Receptors, Growth Factor [D12.776.543.750.750.400] * Receptors, Somatomedin [D12.776.543.750.750.400.780] * Receptor, IGF Type ...
Mannose-6-Phosphate Receptor Receptor, IGF-II Receptor, Insulin-Like Growth Factor II Receptor, Insulin-Like Growth Factor Type ... The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF ... The receptor is a 250-kDa single chain polypeptide which is unrelated in structure to the type 1 IGF receptor (RECEPTOR, IGF ... Receptors, Growth Factor [D12.776.543.750.750.400] * Receptors, Somatomedin [D12.776.543.750.750.400.780] * Receptor, IGF Type ...
Receptor, IGF Type 2. [NCBI]. Gene. Gene. Link. Information. Gain. 01. MIR657 [NCBI] 0.000243173 KTWS [NCBI] 0.000180534 IGF2R ... mannose 6-phosphate receptor recognition defect, lebanese type [NCBI] 0.00765877 diabetes mellitus, transient neonatal, 1 [NCBI ... niemann-pick disease, type c2 [NCBI] 0.000134706 SGBS1 [NCBI] 0.000117897 GUSB [NCBI] 0.000102207 CTSL [NCBI] 9.23441e-05 ... golgi-associated, gamma-adaptin ear-containing, arf-binding protein 2 [NCBI] 2.88809e-05 GGA3 [NCBI] 2.78046e-05 CSNK2A2 [NCBI] ...
The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) binds M6P-capped ligands and IGF-II at different ... IGF Type 2 Receptor Medicine & Life Sciences 93% * Insulin-Like Growth Factor II Medicine & Life Sciences 82% ... abstract = "The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) binds M6P-capped ligands and IGF-II at ... N2 - The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) binds M6P-capped ligands and IGF-II at ...
IGF-I) to bind to its receptors. Like insulin, IGF-I also inhibits the livers synthesis of SHBG, whereas both hormones ... Can endogenous hyperinsulinaemia explain the increased risk of cancer development and mortality in type 2 diabetes: evidence ... and/or with elevated levels of bioactive IGF-I. Hyperinsulinemia and an increased IGF-I bioactivity may be linked to a western ... Plasma insulin, IGF-I and breast cancer. *Detection of PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) in the milk of ...
... although glucose transporter type 2 (GLUT2) may also play a role. The membrane potential of small intestinal epithelial cells ( ... Casselbrant proposed that angiotension II combined with the angiotensin type 1 receptor (AT1R) or angiotensin type 2 receptor ( ... Alexander, A.N.; Carey, H.V. Involvement of PI 3-kinase in IGF-I stimulation of jejunal na+-k+-atpase activity and nutrient ... Active intestinal calcium transport in the absence of transient receptor potential vanilloid Type 6 and calbindin-D(9k). ...
Synonyms: Mpr300, CI-MPR, IGF-II/CI-MPR, M6P/IGF2R, CD222, mannose-6-phosphate receptor, cation independent ... When maintaining a live colony, heterozygous mice may be bred together, bred with wild-type siblings, or bred with C57BL/6J ... 2 An aliquot contains a sufficient number of embryos (in one or more vials or straws and based on the transfer success rate of ... Name: phospholipase A2 receptor 1. Synonyms: PLA2-I receptor, M-type receptor, Pla2g1br ...
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II. RECEPTOR, IGF TYPE 2. RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR. RECEPTOR, ... RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I. RECEPTOR, IGF TYPE 1. ... RECEPTOR, EPIDERMAL GROWTH FACTOR. RECEPTORS, INSULIN. RECEPTOR ...
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II. RECEPTOR, IGF TYPE 2. RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR. RECEPTOR, ... RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I. RECEPTOR, IGF TYPE 1. ... RECEPTOR, EPIDERMAL GROWTH FACTOR. RECEPTORS, INSULIN. RECEPTOR ...
RECEPTORS, INSULIN-LIKE-GROWTH-FACTOR II. RECEPTOR, IGF TYPE 2. RECEPTORS, MACROPHAGE COLONY-STIMULATING FACTOR. RECEPTOR, ... RECEPTORS, INSULIN-LIKE-GROWTH FACTOR I. RECEPTOR, IGF TYPE 1. ... RECEPTOR, EPIDERMAL GROWTH FACTOR. RECEPTORS, INSULIN. RECEPTOR ...

No FAQ available that match "receptor igf type 2"

No images available that match "receptor igf type 2"